SofWave Medical Bilan de santé

Santé financière contrôle des critères 6/6

SofWave Medical possède un total de capitaux propres de $24.3M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $39.5M et de $15.2M.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$21.25m
Fonds propres	US$24.27m
Total du passif	US$15.19m
Total des actifs	US$39.46m

Mises à jour récentes de la santé financière

We're Not Worried About SofWave Medical's (TLV:SOFW) Cash Burn

Nov 13

Here's Why We're Not Too Worried About SofWave Medical's (TLV:SOFW) Cash Burn Situation

May 05

Here's Why We're Not Too Worried About SofWave Medical's (TLV:SOFW) Cash Burn Situation

Dec 22

Is SofWave Medical (TLV:SOFW) In A Good Position To Invest In Growth?

Aug 25

Recent updates

Investors Aren't Entirely Convinced By SofWave Medical Ltd.'s (TLV:SOFW) Revenues

Nov 15

We Think Some Shareholders May Hesitate To Increase SofWave Medical Ltd.'s (TLV:SOFW) CEO Compensation

Sep 11

SofWave Medical Ltd. (TLV:SOFW) Screens Well But There Might Be A Catch

May 02

Even With A 27% Surge, Cautious Investors Are Not Rewarding SofWave Medical Ltd.'s (TLV:SOFW) Performance Completely

Jan 31

A Piece Of The Puzzle Missing From SofWave Medical Ltd.'s (TLV:SOFW) 31% Share Price Climb

Nov 17

We're Not Worried About SofWave Medical's (TLV:SOFW) Cash Burn

Nov 13

Here's Why We're Not Too Worried About SofWave Medical's (TLV:SOFW) Cash Burn Situation

May 05

Here's Why We're Not Too Worried About SofWave Medical's (TLV:SOFW) Cash Burn Situation

Dec 22

Is SofWave Medical (TLV:SOFW) In A Good Position To Invest In Growth?

Aug 25

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de SOFW ( $35.2M ) dépassent ses passifs à court terme ( $14.5M ).

Passif à long terme: Les actifs à court terme de SOFW ( $35.2M ) dépassent ses passifs à long terme ( $661.0K ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: SOFW est sans dette.

Réduire la dette: SOFW n'avait aucune dette il y a 5 ans.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: SOFW dispose d'une piste de trésorerie suffisante pour plus de 3 ans sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: SOFW dispose d'une marge de trésorerie suffisante pour plus de 3 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 6.7 % chaque année

SofWave Medical Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

We're Not Worried About SofWave Medical's (TLV:SOFW) Cash Burn

Here's Why We're Not Too Worried About SofWave Medical's (TLV:SOFW) Cash Burn Situation

Here's Why We're Not Too Worried About SofWave Medical's (TLV:SOFW) Cash Burn Situation

Is SofWave Medical (TLV:SOFW) In A Good Position To Invest In Growth?

Recent updates

Third quarter 2024 earnings released: US$0.039 loss per share (vs US$0.036 loss in 3Q 2023)

Investors Aren't Entirely Convinced By SofWave Medical Ltd.'s (TLV:SOFW) Revenues

New minor risk - Share price stability

Sofwave Medical Ltd. Appoints Miguel Pardos to the Role of Chief Commercial Officer

SofWave Medical Ltd. to Report Q3, 2024 Results on Nov 13, 2024

SofWave Medical Ltd. Obtains U.S. Patent for Fat Tissue Reduction Technology

We Think Some Shareholders May Hesitate To Increase SofWave Medical Ltd.'s (TLV:SOFW) CEO Compensation

SofWave Medical Ltd. Appoints Larry Laber to the Role of Executive Vice President, North American Sales

Sofwave Receives FDA Clearance for Pure Impact™ in Strengthening and Firming of Arms in the U.S

Second quarter 2024 earnings released: US$0.045 loss per share (vs US$0.083 loss in 2Q 2023)

First quarter 2024 earnings released: US$0.029 loss per share (vs US$0.11 loss in 1Q 2023)

SofWave Medical Ltd. (TLV:SOFW) Screens Well But There Might Be A Catch

Full year 2023 earnings released: US$0.24 loss per share (vs US$0.57 loss in FY 2022)

SofWave Medical Ltd. Appoints James Bartholomeusz as Chief Innovation Officer

Even With A 27% Surge, Cautious Investors Are Not Rewarding SofWave Medical Ltd.'s (TLV:SOFW) Performance Completely

SofWave Medical Ltd. Receives FDA Clearance of Superb™? Technology for Improvement of the Appearance of Skin Laxity on the Upper Arm

Less than half of directors are independent

SofWave Medical Ltd., Annual General Meeting, Jan 23, 2024

A Piece Of The Puzzle Missing From SofWave Medical Ltd.'s (TLV:SOFW) 31% Share Price Climb

We're Not Worried About SofWave Medical's (TLV:SOFW) Cash Burn

Third quarter 2023 earnings released: US$0.036 loss per share (vs US$0.13 loss in 3Q 2022)

SofWave Medical Ltd. to Report Q3, 2023 Results on Nov 08, 2023

Sofwave Medical Announces FDA Clearance of SUPERB™ Technology For Treatment of Acne Scars

Second quarter 2023 earnings released: US$0.083 loss per share (vs US$0.16 loss in 2Q 2022)

New major risk - Share price stability

SofWave Medical Ltd. to Report Q2, 2023 Results on Aug 08, 2023

Sofwave Medical Ltd. Gains Additional U.S. Patent Protection for the Company's Proprietary SUPERB™ Technology

Less than half of directors are independent

First quarter 2023 earnings released: US$0.11 loss per share (vs US$0.16 loss in 1Q 2022)

Here's Why We're Not Too Worried About SofWave Medical's (TLV:SOFW) Cash Burn Situation

Full year 2022 earnings released: US$0.57 loss per share (vs US$0.29 loss in FY 2021)

SofWave Medical Ltd. Gains Market Approval for SUPERB(TM) Non-Invasive Wrinkle Reduction and Lifting Technology in Mexico

Sofwave Medical Ltd Announces Market Approvals for SUPERB(TM) Non-Invasive Wrinkle Reduction Technology Now Extend to Taiwan

Here's Why We're Not Too Worried About SofWave Medical's (TLV:SOFW) Cash Burn Situation

SofWave Medical Ltd. Announces FDA Clearance of SUPERB™ Technology For Cellulite

SofWave Gains Approval to Market the Superb™ Non-Invasive Wrinkle Reduction Device in Brazil

Sofwave Medical Ltd. Receives Grants U.S. Patent Covering Key Elements of Proprietary Superb™ Non-Surgical Skin and Collagen Remodeling Technology

SofWave Medical Ltd. to Report Q2, 2022 Results on Aug 16, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

SofWave Medical Ltd. to Report Q4, 2022 Results on Mar 09, 2022

Chief Financial Officer Michael Eden has left the company

Is SofWave Medical (TLV:SOFW) In A Good Position To Invest In Growth?

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines